aid: aravax

name: Aravax

description: 'Aravax is a biotechnology company focused on developing next‑generation immunotherapies for food allergies. It aims to revolutionise treatment by using proprietary peptide platforms to retrain the immune system, offering safer and more convenient solutions. The company runs international clinical trials for its lead product PVX108 targeting peanut allergy, with sites in the United States and Australia. Aravax is headquartered in Melbourne, Australia, and also operates in the UK.'

url: https://raw.githubusercontent.com/api-evangelist/aravax/refs/heads/main/apis.yml

x-type: company

x-source: harvest:secondary-market

x-tier: profiled
x-tier-reason: enrichment pass 2026-09-25 (modular-v1; was harvest)

specificationVersion: '0.20'

created: '2026-09-25'

modified: '2026-10-06'

tags:
- Biotechnology
- Immunotherapy
- Food Allergy
- Clinical Trials
- Australia

maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io

common:
- url: https://www.aravax.com.au/feed/
  type: BlogRSS
- type: Hosts
  url: hosts/aravax-hosts.yml
- type: Vendors
  url: vendors/aravax-vendors.yml
- type: Newsroom
  url: https://www.aravax.com.au/news/
- type: Leadership
  url: https://www.aravax.com.au/about-aravax/management/
- type: DomainSecurity
  url: security/aravax-domain-security.yml
- type: Website
  url: https://www.aravax.com.au

apis: []

x-enrichment:
  date: '2026-09-25'
  status: enriched
  artifacts_added: 4
  pass: modular-v1
  engine: identity=local,contract=local,surfaces=local,docs=local
x-coverage:
  state: none
  reason: no-developer-program
  method: derived
  generated: '2026-09-25'
  generator: derive-coverage.py (pre-flight evidence)
  detail: >-
    the company publishes no developer documentation host and no machine-readable contract on its own domain
  evidence:
  - url: https://equityzen.com/company/aravax
    status: 403